Success Story: Strategic RFE Response Leads to EB-1A Approval for a Health Economics and Outcomes Researcher from India
Client’s Testimonial:
"I had a highly satisfactory experience with North America Immigration Law Group (Chen Immigration Law Associates) during my EB-1A petition process. From the outset, an attorney worked closely with me to organize and strengthen my application, carefully identifying the most relevant evidence and aligning it with the applicable criteria for the I-140 petition.
After I received an RFE, my case was transitioned to a specialized attorney with expertise in RFE responses. This attorney provided strategic and focused guidance, ensuring that each concern raised by USCIS was addressed thoroughly and effectively. The RFE response team carefully evaluated my existing documentation, identified the strongest supporting evidence, and presented it in a clear and persuasive manner tailored to the specific issues outlined in the RFE.
Overall, the team demonstrated a high level of professionalism, attention to detail, and strategic insight throughout the process, which contributed significantly to my case approval.”
On March 20th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for a Senior Specialist in the Field of Control of Health Economics and Outcomes Research (Approval Notice).
General Field: Health Economics and Outcomes Research
Position at the Time of Case Filing: Senior Specialist
Country of Origin: India
State of Residence at the Time of Filing: West Virginia
Approval Notice Date: March 20th, 2026
Processing Time: 3 months, 27 days (Premium Processing Requested)
Case Summary:
When our client, a Senior Health Economics and Outcomes Research Specialist from India, received a Request for Evidence challenging the significance of his work and the importance of his role, North America Immigration Law Group (Chen Immigration Law Associates) responded with a focused and evidence-driven strategy. By carefully strengthening the record with objective data and expert support, we were able to turn a difficult stage of the case into a successful EB-1A approval.
The RFE focused first on whether the client’s work rose to the level of original contributions of major significance. Our client holds a Ph.D. in health services and outcomes research and has built his work around health informatics and artificial intelligence in healthcare. His research has addressed important issues such as the use of electronic health records for clinical research, the development of natural language processing pipelines to identify self-reported COVID-19 vaccine side effects, and budgetary analyses for chronic disease treatments. To further underscore the importance of this work, we highlighted that one of the studies to which he made significant contributions received funding from the National Institutes of Health.
To reinforce the impact of his research, we submitted strong bibliometric evidence. The record showed that he had authored 19 peer-reviewed journal articles and 30 abstracts, with 218 citations from researchers in 25 countries. We also demonstrated that two of his papers ranked among the top 10% most highly cited articles in Computer Science for their respective publication years.
The RFE also challenged whether he had performed in a leading or critical role. In response, we obtained a detailed letter from company leadership explaining how his real-world evidence analyses directly supported regulatory strategy and market access efforts for important technologies. We also showed that his cost-effectiveness models had been presented at major international conferences, further supporting the argument that his work played a direct role in the organization’s scientific visibility and success.
In addition, we addressed concerns regarding the high salary criterion by providing detailed wage data showing that his base salary exceeded the top 10% threshold for comparable professionals nationwide. We also strengthened the judging criterion with documentation confirming that he had completed at least 36 reviews for respected journals and conferences, reflecting the trust placed in his expertise by the broader field.
As one independent expert observed, “Overall, this research strengthens the nation’s ability to monitor vaccine safety and respond effectively to current and public health challenges.”
By methodically addressing each issue raised in the RFE with targeted evidence, we secured a successful EB-1A approval for this client. We congratulate him on this achievement and look forward to his continued contributions to healthcare economics and public health research in the United States.